Amy Flaxman
Postdoctoral scientist
I have always been interested in translational research – how can what I am doing at the bench have an impact at the bedside? After studying Molecular and Cellular Biology at the University of Bath, I worked for several years in academia and industry building my laboratory skills base. I came to the Jenner Institute and undertook my DPhil studies investigating the impact of S. aureus colonisation and how this impacts vaccination. The aim was to study how pre-existing exposure to the bacterium can impact on subsequent vaccination against it.
For my post-doctoral research I have worked on both pre-clinical studies developing vaccines for outbreak pathogens, such as Ebola, and clinical trials for pre-erythrocytic Malaria and outbreak pathogens, including MERS and Ebola.
I am continuing my research in Teresa Lambe’s group working on immune responses to the Oxford ChAdOx1-nCoV vaccine for SARS-CoV-2 currently in Phase III clinical trials. I lead the lab team carrying out antibody testing post-vaccination. Here, I am interested in the differences in antibody responses induced over time with different doses of vaccine, in different age groups and how this changes with administration of a booster vaccine. We are also interested in cross-reactive immune responses to other circulating coronaviruses which cause mild disease.
Recent publications
-
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Journal article
Ramasamy MN. et al, (2020), The Lancet, 396, 1979 - 1993
-
Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.
Journal article
Folegatti PM. et al, (2020), The Lancet. Infectious diseases, 20, 816 - 826
-
A Multi-Filovirus Vaccine Candidate: Co-Expression of Ebola, Sudan, and Marburg Antigens in a Single Vector
Journal article
Sebastian S. et al, (2020), Vaccines, 8, 241 - 241
-
Safety and Immunogenicity of the Heterosubtypic Influenza A Vaccine MVA-NP+M1 Manufactured on the AGE1.CR.pIX Avian Cell Line
Journal article
Folegatti PM. et al, (2019), Vaccines, 7, 33 - 33
-
Heterogeneous early immune responses to the S. aureus EapH2 antigen induced by gastrointestinal tract colonisation impact the response to subsequent vaccination
Journal article
Flaxman A. et al, (2019), Vaccine, 37, 494 - 501